Physician profile
Samson Dankert
NPI 1720703846
$8,687.10
in general payments reported to CMS, 2019-2025
24 companies · $3,648 in 2025
The $3,648 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,747 · 2024: $3,292 · 2025: $3,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,770 · Consulting Fee: $500 · Education: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,770.00 |
| Consulting Fee | $500.00 |
| Education | $417.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,578.73 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,093.84 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,064.92 | 2023-2025 | |
| Abbvie INC. | $1,058.29 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $625.20 | 2024-2025 | Sotyktu |
| Incyte Corporation | $599.11 | 2024-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $450.22 | 2023-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $415.19 | 2023-2025 | |
| Dermavant Sciences, INC. | $254.06 | 2023-2024 | Vtama |
| Lilly USA, LLC | $197.55 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $189.51 | 2025 | Bimzelx |
| Genzyme Corporation | $183.49 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $181.04 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $173.32 | 2024-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $126.86 | 2023-2025 | Ycanth |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.36 | 2024-2025 | Otezla |
| Paratek Pharmaceuticals, INC. | $95.05 | 2024 | Nuzyra |
| Galderma Laboratories, L.P. | $82.03 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $72.80 | 2025 | Vtama |
| Biocon Biologics INC | $43.50 | 2024 | Hulio |
| Phadia US INC. | $28.80 | 2024-2025 | Immunocap |
| Fresenius Kabi USA, LLC | $22.23 | 2024 | Idacio |
| Lnhc, INC | $13.88 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.12 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samson Dankert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.